Analgesic Efficacy of Blocking Nerve to Vastus Lateralis Muscle Versus Lateral Femoral Cutaneous Nerve After Knee Surgeries

Analgesic Efficacy of Blocking Nerve to Vastus Lateralis Muscle Versus Lateral Femoral Cutaneous Nerve After Knee Surgeries: A Randomized Trial

This study aims to compare the analgesic efficacy and functional outcomes of blocking the nerve to the vastus lateralis (NVL) muscle versus the lateral femoral cutaneous nerve (LFCN).

Study Overview

• Status: Recruiting
• Conditions: Analgesia; Lateral Femoral Cutaneous Nerve Block; Vastus Lateralis Nerve Block; Knee Surgeries
• Intervention / Treatment: Drug: Vastus lateralis nerve block; Drug: Lateral femoral cutaneous nerve block

Detailed Description

Knee surgeries are associated with significant postoperative pain, which can impede early mobilization and prolong recovery. Recent advancements in ultrasound-guided regional anesthesia have enabled more targeted nerve blocks, such as the blockade of the nerve to the vastus lateralis (NVL) and the lateral femoral cutaneous nerve (LFCN)

• Study Type: Interventional
• Enrollment (Estimated): 80
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Sherif K Arafa, MD; Phone Number: 00201005714014; Email: Sherifhafez1980@gmail.com

Study Locations

• Egypt
  • Kafrelsheikh
    • Kafr Ash Shaykh, Kafrelsheikh, Egypt, 33516
      • Recruiting
      • Kafrelsheikh University
      • Contact: Sherif K Arafa, MD; Phone Number: 00201005714014; Email: Sherifhafez1980@gmail.com

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Age ≥ 18 years.
• Both sexes.
• American Society of Anesthesiologists (ASA) physical status from I to III.
• Underwent knee surgeries under spinal anesthesia.

Exclusion Criteria:

• Pregnancy.
• Coagulopathy.
• Neuromuscular disorders.
• Hematological disorders.
• Mental disorders.
• History of multiple traumas or anesthesia drug allergies.
• Local skin infection at the block site.
• Body mass index (BMI) greater than 40.
• Opioid analgesics or abusing opioids.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Double

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Vastus lateralis nerve block group; Patients will receive vastus lateralis nerve block.	Drug: Vastus lateralis nerve block; Patients received vastus lateralis nerve block with 5 ml of bupivacaine 0.5%.; Other Names: Bupivacaine 0.5%
Experimental: Lateral femoral cutaneous nerve block group; Patients will receive lateral femoral cutaneous nerve.	Drug: Lateral femoral cutaneous nerve block; Patients received lateral femoral cutaneous nerve block with 5 ml of bupivacaine 0.5%.; Other Names: Bupivacaine 0.5%

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Degree of pain	Each patient will be instructed about postoperative pain assessment using the numeric rating scale (NRS) score (0 represents "no pain" while 10 represents "the worst pain imaginable"). NRS assessments will be conducted at the post-anesthesia care unit (PACU) and at 2, 4, 6, 12, 18, and 24 hours postoperatively.	24 hours postoperatively

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Time to first request for analgesia	The time to first request for analgesia will be recorded from the end of surgery till the first dose of morphine is administered.	24 hours postoperatively
Total morphine consumption	If the numeric rating scale (NRS) exceeded 3, rescue analgesia in the form of a 3 mg morphine bolus will be administered, to be repeated after 30 minutes if the pain persisted until the NRS dropped below 4.	24 hours postoperatively
Block performance time	The block performance time will be recorded from the placement of the ultrasound probe to the removal of the needle after the injection of local anaesthetic.	Intraoperatively
Degree of patient satisfaction	The degree of patient satisfaction will be measured using a 5-point Likert scale (1 = extremely dissatisfied, 2 = unsatisfied, 3 = neutral, 4 = satisfied, 5 = extremely satisfied).	24 hours postoperatively
Length of hospital stay	Length of hospital stay will be recorded from admission till discharge from the hospital.	Till the discharge from hospital (Up to one week).
Incidence of adverse events	Incidence of adverse events such as postoperative nausea and vomiting (PONV), respiratory depression, and local anesthetic (LA) toxicity will be recorded.	24 hours postoperatively

Collaborators and Investigators

• Sponsor: Kafrelsheikh University

Study record dates

Study Major Dates

• Study Start (Actual): February 5, 2025
• Primary Completion (Estimated): July 30, 2025
• Study Completion (Estimated): July 30, 2025

Study Registration Dates

• First Submitted: January 30, 2025
• First Submitted That Met QC Criteria: January 30, 2025
• First Posted (Actual): March 25, 2025

Study Record Updates

• Last Update Posted (Actual): March 25, 2025
• Last Update Submitted That Met QC Criteria: February 5, 2025
• Last Verified: February 1, 2025

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Physiological Effects of Drugs; Peripheral Nervous System Agents; Anesthetics, Local; Anesthetics; Central Nervous System Depressants; Sensory System Agents; Bupivacaine
• Other Study ID Numbers: MKSU 50-1-4

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES
• IPD Plan Description: The data will be available upon a reasonable request from the corresponding author after the end of study for one year.
• IPD Sharing Time Frame: After the end of study for one year.
• IPD Sharing Access Criteria: The data will be available upon a reasonable request from the corresponding author.
• IPD Sharing Supporting Information Type: STUDY_PROTOCOL

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No